Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure (I).
Abstract: Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
Type:
Grant
Filed:
August 20, 2018
Date of Patent:
October 8, 2019
Assignee:
Lixte Biotechnology, Inc.
Inventors:
Alan F. List, David A. Sallman, John S. Kovach
Abstract: A method of treating a depressive or stress disorder in a subject afflicted therewith comprising administering to the subject an effective amount of a compound having the structure:
Type:
Grant
Filed:
November 17, 2017
Date of Patent:
September 17, 2019
Assignee:
Lixte Biotechnology, Inc.
Inventors:
John S. Kovach, Salvatore Lecca, Manuel Mameli
Abstract: Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
Type:
Application
Filed:
August 20, 2018
Publication date:
February 14, 2019
Applicants:
H. Lee Moffitt Cancer Center and Research Institute, Inc., Lixte Biotechnology, Inc.
Inventors:
Alan F. List, David A. Sallman, John S. Kovach
Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure:
Abstract: The present invention provides a process for producing the compound having the structure: comprising (a) reacting a compound having the structure: with a compound having the structure: in the presence of a first organic solvent under conditions sufficient to produce the compound, wherein the first organic solvent is a substituted benzene.
Abstract: A method of treating a depressive or stress disorder in a subject afflicted therewith comprising administering to the subject an effective amount of a compound having the structure:
Type:
Grant
Filed:
February 19, 2016
Date of Patent:
December 5, 2017
Assignees:
LIXTE BIOTECHNOLOGY, INC., INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
Inventors:
John S Kovach, Salvatore Lecca, Manuel Mameli
Abstract: Disclosed are methods for treating a myelodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
Type:
Application
Filed:
July 23, 2015
Publication date:
November 30, 2017
Applicants:
H. Lee Moffitt Cancer Center and Research Institute, Inc., Lixte Biotechnology, Inc.
Inventors:
Alan F. List, David A. Sallman, John S. Kovach
Abstract: The present invention provides a process for producing the compound having the structure: comprising (a) reacting a compound having the structure: with a compound having the structure: in the presence of a first organic solvent under conditions sufficient to produce the compound, wherein the first organic solvent is a substituted benzene.
Abstract: Disclosed herein are methods of inhibiting proliferation of a cancer cell or inducing apoptosis of a cancer cell, which does not overexpress N—CoR. Also disclosed herein are methods of inhibiting proliferation or inducing apoptosis of a cancer cell that overexpresses TCTP and methods for determining whether a compound is effective in inducing cell death.